Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients 

Authors: Gaye Hafez, Jolanta Malyszko, Aleksandra Golenia, Aleksandra Klimkowicz-Mrowiec, Ana Carina Ferreira, Mustafa Arıcı, Annette Bruchfeld, Dorothea Nitsch, Ziad A Massy, Marion Pépin, 

Giovambattista Capasso, Laila-Yasmin Mani, Sophie Liabeuf, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target)

The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects.

View publication here.

Latest Updates


Fifth Call for Short-Term Scientific Mission

Fifth Call for Short-Term Scientific Mission (STSM) applications within the COST Action “Cognitive decline in Nephro-Neurology: European Cooperative Target (CONNECT)” Deadline for submission: April 13th, 2024

Read More

Efficacy of erythropoietin as a neuroprotective agent in CKD-associated cognitive dysfunction: A literature systematic review

Authors: Michelangela Barbieri, Paolo Chiodini, Piergiacomo Di Gennaro, Gaye Hafez, Sophie Liabeuf, Jolanta Malyszko, Laila-Yasmin Mani, Francesco Mattace Raso, Marion Pepin, Norberto Perico, Mariadelina Simeoni, Carmine Zoccali, Giovanni Tortorella, Annalisa Capuano, Giuseppe Remuzzi, Giovambattista Capasso, Giuseppe Paolisso, on behalf of CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target) collaborators Patients with chronic kidney disease (CKD) often experience

Read More